Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Ana Drozdowskyj, Enric Carcereny et al.|The Lancet Oncology|2012Cited by 5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung CancerRafael Rosell, Miquel Tarón, Teresa Morán et al.|New England Journal of Medicine|2009Cited by 2.4k
Tumor Markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in Patients with Non-Small Cell Lung Cancer as an Aid in Histological Diagnosis and PrognosisRafael Molina, P. Viladiu, Vı́ctor Moreno et al.|Tumor Biology|2003Cited by 274